The following is the transcript of an interview with FDA commissioner Dr. Marty Makary that aired on "Face the Nation with ...

Moderna receives FDA approval for lower-dose COVID-19 vaccine, mNexspike, with restrictions on who can receive it.

One of the unmet needs in this field is the lack of a robust, sensitive, and multiplexed method for EV mRNA profiling. We established a new protocol using the NanoString low RNA input nCounter assay ...

The success of these COVID-19 vaccines is remarkable and was far from guaranteed. mRNA is incredibly delicate. Enzymes in the environment and in our bodies are quick to chop mRNA into pieces ...

The FDA is requiring COVID vaccine makers Pfizer and Moderna to update their warnings about the possible risk of myocarditis ...

In early trading on Monday, shares of Moderna topped the list of the day's best performing components of the S&P 500 index, trading up 7.3%. Year to date, Moderna has lost about 35.8% of its value ...

Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue ...

3 investigational HIV-1 trimer mRNA vaccines induced mild- to moderate-adverse effects in a phase 1, randomized trial. HealthDay News — Urticaria is seen in association with experimental HIV-1 mRNA ...

Arcturus Therapeutics is scaling back work on early-stage candidates and will instead dedicate its resources to its more developed mRNA therapies, the biotech announced Tuesday alongside its ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway.

AAP FACTCHECK - The US drug regulator has not admitted that "shedding" from COVID-19 mRNA vaccines causes side effects to unvaccinated people, despite claims on social media. The US Food and Drug ...